Skip to content
Peptigraph home

MOTS-c and Retatrutide Together: What Is Known

MOTS-c and Retatrutide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Mitochondrial-derived peptidePCAC voted 7–5 for 503A (Jul 2026)MOTS-cMitochondrial-derived peptide; human studies found only measured the body's own circulating levels (for example after repeated heat treatment), not administered MOTS-c.[8]GLP-1 & metabolicGLP-1 / GIP / glucagon triple agonistInvestigational · phase 3RetatrutideInvestigational triple GIP, GLP-1 and glucagon receptor agonist, not FDA-approved; a phase 3 TRIUMPH trial reported mean weight change of -25.0% at the 12-mg dose versus -3.9% with placebo.[1]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 11 of 13 fields where the two differ. Category, Evidence strength are the same or both unknown.

FieldMOTS-cRetatrutide
ClassMitochondrial-derived peptideGLP-1 / GIP / glucagon triple agonist
Also calledmotsreta, GLP-3, LY3437943
FDA statusPCAC voted 7–5 for 503A (Jul 2026)Investigational · phase 3
PCAC vote, Jul 2026PCAC voted 7–5 for the 503A list (Jul 2026); not finalizedNot on the Jul 2026 agenda
WADAProhibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times.Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change.
Anti-doping detection
  • A plasma (blood) test for MOTS-c has been validated to WADA standards.PMID 30394592
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeNo published half-life foundPubMed search, 11 Oct 2026approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040
Human studies we summarised7 human (4 randomized or controlled) of 15 summarised11 human (11 randomized or controlled) of 16 summarised
Typical study doses
Vial sizes sold5 mg, 10 mg, 20 mg, 40 mg5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026; 31 Mar 2026)
Related tools

MOTS-c vs Retatrutide

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

Retatrutide: late-phase human trials

TRIUMPH-1 randomised 2339 adults with obesity to retatrutide or placebo and reported weight loss at each of its doses against 3.9% on placebo.[1]

Within TRIUMPH-1, a subgroup with obstructive sleep apnoea showed larger falls in apnoea events per hour than placebo.[1]

MOTS-c: mouse and cell work, not injected-peptide trials in people

The MOTS-c evidence behind this pairing is from mice, where treatment prevented insulin resistance linked to ageing and a high-fat diet.[22]

Its human data measure the body's own circulating MOTS-c, not an injected product: a 16-week exercise trial in breast cancer survivors found levels rose after exercise in one subgroup.[10]

In ageing mice, intermittent MOTS-c treatment started late in life increased physical capacity. This is an animal result.[23]

No study of the pair

A PubMed title and abstract search on 2 Oct 2026 for MOTS-c together with retatrutide returned 0 records.

Calculated from pubmed query ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab]); records matched 0; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

Drugs@FDA has no entry for MOTS-c.[24]

Sport and legal status

WADA lists MOTS-c by name among AMPK activators, banned at all times.[6]

FDA says retatrutide cannot be used in compounding under federal law.[25]

Common questions

Can MOTS-c be taken with retatrutide?

No study has tested it. MOTS-c's human literature measures endogenous levels, and FDA lists retatrutide as unapproved and barred from compounding.[25]

Does MOTS-c help with weight loss in people?

Only mouse data show weight effects; in mice, treatment prevented diet-induced obesity.[22]

Sources

  1. 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  3. 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
  4. 4FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  5. 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  6. 6World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  7. 7Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
  8. 8Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
  9. 9Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
  10. 10Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
  11. 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
  17. 17Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
  18. 18Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
  19. 19PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  20. 20Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
  21. 21PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  22. 22The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.Cell metabolism · 2015PMID 25738459Accessed 2 Oct 2026
  23. 23MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.Nature communications · 2021PMID 33473109Accessed 2 Oct 2026
  24. 24Drugs@FDA (openFDA) search: active ingredient "MOTS-c"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  25. 25Official web pageOfficial web page · web page

Found an error? Report a correction.